DE69129594D1 - Ein bifunktioneller ligand des dtpa typs - Google Patents

Ein bifunktioneller ligand des dtpa typs

Info

Publication number
DE69129594D1
DE69129594D1 DE69129594T DE69129594T DE69129594D1 DE 69129594 D1 DE69129594 D1 DE 69129594D1 DE 69129594 T DE69129594 T DE 69129594T DE 69129594 T DE69129594 T DE 69129594T DE 69129594 D1 DE69129594 D1 DE 69129594D1
Authority
DE
Germany
Prior art keywords
bifunctional ligand
dtpa
type
dtpa type
bifunctional
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69129594T
Other languages
English (en)
Other versions
DE69129594T2 (de
Inventor
Otto A Gansow
Martin W Brechbiel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
US Department of Commerce
Original Assignee
US Department of Health and Human Services
US Department of Commerce
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services, US Department of Commerce filed Critical US Department of Health and Human Services
Publication of DE69129594D1 publication Critical patent/DE69129594D1/de
Application granted granted Critical
Publication of DE69129594T2 publication Critical patent/DE69129594T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/534—Production of labelled immunochemicals with radioactive label
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A61K51/048—DTPA (diethylenetriamine tetraacetic acid)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/16—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of hydrocarbon radicals substituted by amino or carboxyl groups, e.g. ethylenediamine-tetra-acetic acid, iminodiacetic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C331/00—Derivatives of thiocyanic acid or of isothiocyanic acid
    • C07C331/16—Isothiocyanates
    • C07C331/28—Isothiocyanates having isothiocyanate groups bound to carbon atoms of six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
DE69129594T 1990-03-26 1991-03-22 Ein bifunktioneller ligand des dtpa typs Expired - Lifetime DE69129594T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/498,319 US5124471A (en) 1990-03-26 1990-03-26 Bifunctional dtpa-type ligand
PCT/US1991/001919 WO1991014459A1 (en) 1990-03-26 1991-03-22 A bifunctional dtpa-type ligand

Publications (2)

Publication Number Publication Date
DE69129594D1 true DE69129594D1 (de) 1998-07-16
DE69129594T2 DE69129594T2 (de) 1998-11-05

Family

ID=23980556

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69129594T Expired - Lifetime DE69129594T2 (de) 1990-03-26 1991-03-22 Ein bifunktioneller ligand des dtpa typs

Country Status (10)

Country Link
US (3) US5124471A (de)
EP (1) EP0587555B1 (de)
JP (1) JPH075527B2 (de)
AT (1) ATE167063T1 (de)
AU (1) AU638127B2 (de)
CA (1) CA2078996C (de)
DE (1) DE69129594T2 (de)
DK (1) DK0587555T3 (de)
ES (1) ES2117009T3 (de)
WO (1) WO1991014459A1 (de)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342604A (en) * 1988-10-31 1994-08-30 The Dow Chemical Company Complexes possessing ortho ligating functionality
US5811387A (en) * 1990-05-15 1998-09-22 Chiron Corporation Peptoid mixtures
US5292938A (en) * 1992-04-13 1994-03-08 Associated Universities, Inc. Synthesis of 4-substituted-trans-1, 2-diaminocyclohexyl polyaminocarboxylate metal chelating agents for the preparation of stable radiometal antibody immunoconjugates for therapy and spect and pet imaging
US7744877B2 (en) * 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
DK0669836T3 (da) * 1992-11-13 1996-10-14 Idec Pharma Corp Terapeutisk anvendelse af kimære og radioaktivt mærkede antistoffer og humant B-lymfocytbegrænset differentieringsantigen til behandling af B-cellelymfom
DE4302289A1 (de) * 1993-01-25 1994-07-28 Schering Ag Verfahren zur Herstellung C-substituierter Diethylentriamine
DE4302287A1 (de) * 1993-01-25 1994-07-28 Schering Ag Derivatisierte DTPA-Komplexe, diese Verbindungen enthaltende pharmazeutische Mittel, ihre Verwendung und Verfahren zu deren Herstellung
CA2154896A1 (en) * 1993-01-28 1994-08-04 Robert Allen Snow Immunoreactive reagents employing heterodimers
IL106692A (en) * 1993-08-13 1997-04-15 Israel Atomic Energy Comm AZIDOALKYL DERIVATIVES AND THEIR USE FOR THE PREPARATION OF 99mTc COMPLEXES FOR IMAGING
US5476644A (en) * 1994-04-13 1995-12-19 Sterling Winthrop Inc. Cyclic triamine chelating agents
DE19505960A1 (de) 1995-02-21 1996-08-22 Deutsches Krebsforsch Konjugat zur individuellen Dosierung von Arzneimitteln
DE19507820A1 (de) * 1995-02-21 1996-08-22 Schering Ag Neuartig substituierte DTPA-Derivate, deren Metallkomplexe, diese Komplexe enthaltende pharmazeutische Mittel, deren Verwendung in der Diagnostik, sowie Verfahren zur Herstellung der Komplexe und Mittel
US20010023288A1 (en) * 1999-07-07 2001-09-20 Wilbur D. Scott Trifunctional reagent for conjugation to a biomolecule
WO2000002050A1 (en) * 1998-07-07 2000-01-13 Department Of Radiation Oncology, University Of Washington Trifunctional reagent for conjugation to a biomolecule
DE19911329A1 (de) * 1998-03-27 2000-09-21 Benes Ivan Friedrich Humantherapeutisch anwendbares Radioimmunkonjugat und Verfahren zu seiner Herstellung
ATE414536T1 (de) 1998-08-11 2008-12-15 Biogen Idec Inc Kombinationstherapien gegen b-zell-lymphome beinhaltend die verabreichung von anti-cd20- antikörpern
EP2055313B1 (de) 1998-11-09 2015-04-29 Biogen Idec Inc. Behandlung hämatologischer Bösartigkeiten assoziiert mit zirkulierenden Tumorzellen unter Verwendung chimärer anti-CD20 Antikörper
MY155913A (en) * 1998-11-09 2015-12-15 Biogen Inc Chimeric anti-cd20 antibody treatment of patients receiving bmt or pbsc transpants
US20020102208A1 (en) * 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
MY133346A (en) * 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US6207858B1 (en) * 1999-03-03 2001-03-27 Idec Pharmaceuticals Corporation Regioselective synthesis of DTPA derivatives
EP1918305A1 (de) 1999-08-11 2008-05-07 Biogen Idec Inc. Neue klinische Parameter zur Bestimmung der hämatologischen Toxizität vor einer Strahlenimmuntherapie
US6451284B1 (en) 1999-08-11 2002-09-17 Idec Pharmaceuticals Corporation Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
EP2264070A1 (de) 1999-08-11 2010-12-22 Biogen-Idec Inc. Behandlung eines intermediären und hochgradigen Non-Hodgkins-Lymphoms mit Anti-CD20-Antikörper
US6680993B2 (en) 1999-11-30 2004-01-20 Stanley Satz Method of producing Actinium-225 and daughters
AUPQ582400A0 (en) * 2000-02-24 2000-03-16 Biotech Australia Pty Limited A method of treatment and agents for use therein
WO2001074388A1 (en) * 2000-03-31 2001-10-11 Idec Pharmaceuticals Corporation Combined use of anti-cytokine antibodies or antagonists and anti-cd20 for the treatment of b cell lymphoma
WO2001097858A2 (en) * 2000-06-20 2001-12-27 Idec Pharmaceuticals Corporation Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
DE10037832C2 (de) * 2000-08-03 2003-08-21 Karlsruhe Forschzent Kontrastmittel für medizinische Diagnostik und dessen Verwendung
JP4463475B2 (ja) 2001-01-31 2010-05-19 バイオジェン アイデック インコーポレイテッド 腫瘍疾患の治療における免疫調節性抗体の使用
PL373835A1 (en) 2001-01-31 2005-09-19 Biogen Idec Inc. Use of cd23 antagonists for the treatment of neoplastic disorders
US20020159996A1 (en) 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20030003097A1 (en) * 2001-04-02 2003-01-02 Idec Pharmaceutical Corporation Recombinant antibodies coexpressed with GnTIII
WO2002080987A1 (en) * 2001-04-09 2002-10-17 Progenics Pharmaceuticals, Inc. Anti-cd19 immunotoxins
JP2004534808A (ja) * 2001-06-22 2004-11-18 シエーリング アクチエンゲゼルシャフト （エチレン）−（プロピレン）−トリアミン五酢酸誘導体類、それらの製造方法、及び医薬剤の製造のためへのそれらの使用
EP1420688A4 (de) * 2001-06-25 2005-08-31 Us Gov Health & Human Serv Makromolekulare abbildungsmittel für die leberabbildung
US20030194371A1 (en) * 2001-07-10 2003-10-16 Schering Ag (Ethylene)-(propylene) - triaminepentaacetic acid derivatives, process for their production, and their use for the production of pharmaceutical agents
US20040161776A1 (en) 2001-10-23 2004-08-19 Maddon Paul J. PSMA formulations and uses thereof
EP3184539A3 (de) 2001-10-23 2017-09-13 PSMA Development Company L.L.C. Psma antikörper
EP2022799A2 (de) 2001-11-16 2009-02-11 Biogen Idec Inc. Polycistronische Expression von Antikörpern
EP1545498A4 (de) * 2002-09-06 2006-09-06 Us Gov Health & Human Serv Gerüst-substituierte bifunktionale dota-liganden, ihre komplexe und zusammensetzungen und ihre anwendungsverfahren
US7371225B2 (en) 2002-09-24 2008-05-13 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method for convection enhanced delivery of therapeutic agents
CA2514062A1 (en) * 2003-01-27 2004-08-12 Biogen Idec Ma Inc. Compositions and methods for treating cancer using igsf9 and liv-1
EP1613750B1 (de) 2003-03-19 2015-10-14 Amgen Fremont Inc. Antikörper gegen das t-zellen-immunglobulindomäne- und mucindomäne-1 (tim-1) antigen und verwendungen davon
BRPI0416243A (pt) 2003-11-05 2007-01-09 Palingen Inc método de tratamento de um paciente humano que sofre de uma condição que inclui uma hiper-proliferação de células b; formulação farmacêutica para injeção parenteral; kit para o tratamento de um paciente que sofre de uma condição que inclui uma hiper-proliferação de células b; e método para purgar a medula óssea de um paciente que sofre de cáncer linfóide de células b malignas antes do reimplante da medula óssea no paciente após a terapia mieloablativa
US7259249B2 (en) 2003-12-01 2007-08-21 Immunomedics, Inc. Method for preparing conjugates of proteins and chelating agents
US20050171424A1 (en) * 2004-01-13 2005-08-04 The Gov. Of The Usa As Rep. By The Secretary Of The Dept. Of Health And Human Services Methods for imaging the lymphatic system using dendrimer-based contrast agents
AU2005304973A1 (en) 2004-11-05 2006-05-18 Palingen, Inc. Antibody induced cell membrane wounding
WO2006056443A2 (en) * 2004-11-24 2006-06-01 Aplagen Gmbh Method for solid-phase peptide synthesis and purification
DE602005022928D1 (de) 2004-11-30 2010-09-23 Abgenix Inc Antikörper gegen gpnmb und ihre verwendungen
EP2311881A3 (de) 2005-01-05 2011-07-27 Biogen Idec MA Inc. Cripto-bindende Moleküle
US7906343B2 (en) * 2005-01-24 2011-03-15 Sri International Surface-enhanced lanthanide chelates
US20060204443A1 (en) * 2005-03-11 2006-09-14 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Methods for tumor treatment using dendrimer conjugates
CN102989018A (zh) * 2005-08-03 2013-03-27 Rq生物科技有限公司 用于诊断IgA和IgM介导的肾脏疾病的方法和组合物
JP2009515897A (ja) 2005-11-10 2009-04-16 キュラジェン コーポレイション Ｔ細胞の免疫グロブリンドメインおよびムチンドメイン１（ｔｉｍ−１）抗原に対する抗体を用いて卵巣癌および腎臓癌を処置する方法
WO2008070384A2 (en) * 2006-11-06 2008-06-12 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method of preparing macromolecular contrast agents and uses thereof
US20100092384A1 (en) * 2007-03-19 2010-04-15 The Junited States Of America As Represented By Secretary, Dept. Of Health And Human Service Multifunctional nanoparticles and compositions and methods of use thereof
US8535639B2 (en) * 2007-07-17 2013-09-17 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Trifunctional imaging agent for monoclonal antibody tumor-targeted imaging
KR20090123171A (ko) * 2008-05-27 2009-12-02 경북대학교 산학협력단 Ｄｔｐａ-비스-아미드 리간드를 포함하는 가돌리늄 착물과그 합성방법
EP3381933B1 (de) 2008-06-24 2020-06-03 Technische Universität München Muteine von hngal und verwandte proteine mit affinität für ein gegebenes target
WO2010027513A2 (en) 2008-09-08 2010-03-11 Psma Development Company, Llc Methods for killing psma-expressing, taxane-resistant cancer cells
CA3013992A1 (en) 2008-12-30 2010-07-08 Children's Medical Center Corporation Method of predicting acute appendicitis
US20120003235A1 (en) 2008-12-31 2012-01-05 Biogen Idec Ma Inc. Anti-lymphotoxin antibodies
CN101914153B (zh) * 2010-07-05 2012-07-04 吉林大学 一种Pb2+抗原和相应单克隆抗体及其制备方法
US9738707B2 (en) 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
JP6335796B2 (ja) 2012-02-08 2018-06-06 アイジーエム バイオサイエンシズ インク．Ｉｇｍ Ｂｉｏｓｃｉｅｎｃｅｓ Ｉｎｃ． Ｃｄｉｍ結合タンパク質及びその使用
US20150110814A1 (en) 2013-10-18 2015-04-23 Psma Development Company, Llc Combination therapies with psma ligand conjugates
JP6908964B2 (ja) 2013-10-18 2021-07-28 ピーエスエムエー ディベロップメント カンパニー，エルエルシー Ｐｓｍａリガンドコンジュゲートによる併用療法
US20150147339A1 (en) 2013-11-15 2015-05-28 Psma Development Company, Llc Biomarkers for psma targeted therapy for prostate cancer
CN110845615B (zh) 2014-03-21 2023-10-20 艾伯维公司 抗-egfr抗体及抗体药物偶联物
US20200121803A1 (en) 2016-06-08 2020-04-23 Abbvie Inc. Anti-cd98 antibodies and antibody drug conjugates
SG11201810970WA (en) 2016-06-08 2019-01-30 Abbvie Inc Anti-egfr antibody drug conjugates
CN109562190A (zh) 2016-06-08 2019-04-02 艾伯维公司 抗egfr抗体药物偶联物
US20200002421A1 (en) 2016-06-08 2020-01-02 Abbvie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
MX2018015274A (es) 2016-06-08 2019-10-07 Abbvie Inc Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
TW202304996A (zh) 2016-06-08 2023-02-01 美商艾伯維有限公司 抗-b7-h3抗體及抗體藥物結合物
EP3469000A1 (de) 2016-06-08 2019-04-17 AbbVie Inc. Anti-b7-h3-antikörper und antikörperarzneimittelkonjugate
BR112018075644A2 (pt) 2016-06-08 2019-04-09 Abbvie Inc. anticorpos anti-cd98 e conjugados de anticorpo e fármaco
US20190153107A1 (en) 2016-06-08 2019-05-23 Abbvie Inc. Anti-egfr antibody drug conjugates
WO2018048879A1 (en) * 2016-09-07 2018-03-15 The Board Of Trustees Of The University Of Illinois Metal chelators for imaging, therapeutics, and bioanalysis
EP3612567A4 (de) 2017-04-19 2020-11-11 Bluefin Biomedicine, Inc. Anti-vtcn1-antikörper und antikörper-wirkstoff-konjugate
KR101931153B1 (ko) 2017-07-03 2018-12-20 한국원자력연구원 아민과 선택적으로 결합하며 티오에테르 결합을 갖는 dtpa 킬레이터 및 이의 제조방법
EP3883961A1 (de) 2018-11-20 2021-09-29 Takeda Vaccines, Inc. Neuartige zika-virus-antikörper und ihre verwendungen
IT201900003905A1 (it) * 2019-03-18 2020-09-18 Univ Degli Studi Del Piemonte Orientale “A Avogadro” Chelanti pentadentati rigidificati utili per la marcatura [Al18F]2+ di biomolecole
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA713093A (en) * 1965-07-06 Dexter Martin Complex forming polyaminopoly-carboxylic acids
DE1155122B (de) * 1960-10-17 1963-10-03 Geigy Ag J R Verfahren zur Herstellung von neuen alicyclischen Polyaminopolyessigsaeuren bzw. deren komplexen Metallverbindungen
FR1303847A (fr) * 1961-10-16 1962-09-14 Geigy Ag J R Nouveau acides polyaminopolyacétiques, leurs complexes métalliques et leur préparation
US4339426A (en) * 1980-03-18 1982-07-13 Regents Of The University Of California Bleomycin analog
US4454106A (en) * 1982-06-07 1984-06-12 Gansow Otto A Use of metal chelate conjugated monoclonal antibodies
US4472509A (en) * 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4849505A (en) * 1984-01-30 1989-07-18 Enzo Biochem, Inc. Detectable molecules, method of preparation and use
US4824986A (en) * 1985-04-26 1989-04-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Metal chelate protein conjugate
US4899755A (en) * 1985-05-08 1990-02-13 The General Hospital Corporation Hepatobiliary NMR contrast agents
US4881175A (en) * 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4831175A (en) * 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5057302A (en) * 1987-02-13 1991-10-15 Abbott Laboratories Bifunctional chelating agents

Also Published As

Publication number Publication date
JPH05504973A (ja) 1993-07-29
ES2117009T3 (es) 1998-08-01
ATE167063T1 (de) 1998-06-15
US5286850A (en) 1994-02-15
DK0587555T3 (da) 1999-03-22
EP0587555A1 (de) 1994-03-23
AU638127B2 (en) 1993-06-17
EP0587555A4 (en) 1994-06-08
US5124471A (en) 1992-06-23
EP0587555B1 (de) 1998-06-10
CA2078996C (en) 1996-05-28
AU7656591A (en) 1991-10-21
US5434287A (en) 1995-07-18
CA2078996A1 (en) 1991-09-27
DE69129594T2 (de) 1998-11-05
WO1991014459A1 (en) 1991-10-03
JPH075527B2 (ja) 1995-01-25

Similar Documents

Publication Publication Date Title
ATE167063T1 (de) Ein bifunktioneller ligand des dtpa typs
DE69110657T2 (de) Filtersackabdichtung.
DE3884233T3 (de) Bifunktionelle chelatbildende Agenzien.
DE3672796D1 (de) Verpackungsmaschinen des types "formen-fuellen-schliessen" in horizontaler linie.
DE69201671T2 (de) Abdichtaufsätze für Filterelemente.
DE68908185T2 (de) Chelat-zusammensetzung.
NL193194B (nl) Stoomstrijkijzer.
DE69111444T2 (de) Gleitringdichtung.
DE69103762D1 (de) Langspaltpresse.
DE3886088D1 (de) Chelate von Dipyridoxylphosphat mit radioaktiven Metallen.
DE59102407D1 (de) Wellenabdichtung.
DE59103077D1 (de) Abnehmbare Anhängerkupplung.
DE68917256T2 (de) Farbfilteranordnung.
DE69113431T2 (de) Filterpatrone.
DE58904366D1 (de) Dichtungsanordnung.
FR2666394B1 (fr) Ensemble d'etancheite.
FR2668831B3 (fr) Plaque double.
NO891706D0 (no) Cyklodekstrinkomplekser av 5-aminoheksahydropyrimidinforbindelser.
IT1228962B (it) Guarnizione per cuscinetto amovibile.
DE69117741T2 (de) Neue vorangeordnete sechszähnige liganden verwendbar in röntgenologischen bildformenden wirkstoffen
NL191929B (nl) Filterbandpers.
DE59101069D1 (de) Verschlussdeckel.
DE69108539D1 (de) Abdichtung.
MY131703A (en) Complexes of the lanthanides with heterocyclic carbenes
FR2661336B1 (fr) Filtre-presse a chambres.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition